Since start of 2017, Celgene (NASDAQ: CELG) had been occupied in strengthening its I&I (inflammation and immunology) portfolio by providing submissions for an NDA (New Drug Application) to the FDA, which includes one of the most crucial upcoming approval dates that Celgene is eager to seek from NDA – ozanimod in multiple sclerosis.
Multiple Sclerosis, this therapeutic segment continues to showcase significant growth opportunity for several biotechnology giants such as Celgene, Biogen (BIIB), AbbVie (ABBV), and Novartis (NVS), with global incidence close to 1.0 million.
If Ozanimod manages to capture large chunk of the market share in the rising multiple sclerosis market, it will have a powerful impact on the stock price of the Celgene and help many constructive diversified portfolios as well as ETFs (i.e Vanguard Growth ETF) to gain positive gains.
Clinical trials for Ozaminod:
With above chart highlighting the relapse rates (annualized) from the phase II trial for ozanimod for patients suffering with relapsing forms of multiples sclerosis.
Moreover, currently, Ozanimod is considered the leading drug in next-generation sphingosine-1-phosphate receptor 1 (or S1P1) modulators. And the phase 3 SUNBEAM & RADIANCE trials are fully enrolled for evaluating the drug (ozanimod) for multiple sclerosis indication with results expected to be released in 1H of 2017.
Also in 2017, Celgene expects to release data from its phase 2 trial STEPSTONE, which was enrolled for evaluating ozanimod in Crohn’s disease. Plus, the Company has projected that it will complete enrollment of human subjects in its Phase 3 TRUE NORTH trial, which will explore ozanimod’s potential as an ulcerative colitis therapy.
Tinge Research 